Immuron hires Pullan Consulting to find IMM-529 partner for C. diff drug

Immuron Limited announced on July 6, 2026 that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529.¹ Pullan Consulting is described as a life sciences advisory firm with a track record of executing between five and twelve partnering transactions annually over the past 20 years.¹

Immuron already holds U.S. FDA approval for IMM-529's Investigational New Drug application (IND 32095) for clinical development as a product to prevent or treat CDI in a Phase 2 clinical trial.¹ The company has completed preparatory work, having completed an Investigational Brochure and clinical protocol and secured a principal investigator and three Australian sites,¹ and has manufactured and released drug product for supply of a clinical trial.¹

The planned trial design is a randomized, double blind, placebo-controlled study of IMM-529 with standard of care for CDI in subjects with first episode or recurrent CDI, enrolling up to 60 subjects in a 2:1 ratio of IMM-529 plus SOC versus placebo plus SOC.¹ The primary objective is to evaluate safety and tolerability, with efficacy assessed through mortality rate, disease symptoms and recurrence rate.¹

Immuron cited a Lumanity opportunity assessment estimating that up to approximately 98,000 patients would be eligible if IMM-529 is positioned at first recurrence, with projected base case yearly revenue of US$400 million.¹

The company noted comparable licensing structures in the CDI space, stating upfront payments in past deals ranged from USD $1 million to $50 million, with milestone payments ranging from USD $25 million to $570 million, plus typical royalties in the mid to high single digit percentage range.¹